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Both genetic and epigenetic factors are important regulators of the immune system. There is an increasing body of evidence
attesting to epigenetic modiﬁcations that inﬂuence the development of distinct innate and adaptive immune response cells.
Chromatin remodelling via acetylation, methylation, phosphorylation, and ubiquitination of histone proteins as well as DNA,
methylation is epigenetic mechanisms by which immune gene expression can be controlled. In this paper, we will discuss the role
of epigenetics in the regulation of host immunity, with particular emphasis on histone deacetylase inhibitors.In particular, the role
of HDAC inhibitors as a new class of immunomodulatory therapeutics will also be reviewed.
1.Introduction
It is clear that modulation of gene transcription is an essen-
tial component of many biological processes. The onset of
many pathological conditions such as cancer and chronic
inﬂammation often results from aberrant gene transcription.
Integral to this process are epigenetic factors involving two
critical enzymes, histone acetyltransferases (HAT) and his-
tone deacetylases (HDAC). These produce posttranslational
modiﬁcations on histone proteins and result in changes
t oc h r o m a t i ns t r u c t u r ea n df u n c t i o n[ 1, 2]. While HAT
serves to acetylate the N-terminal histone tail, conferring
a “relaxed” chromatin structure that allows transcriptional
activation, HDAC has the opposite eﬀect and represses
transcription through tightening of the chromatin structure,
excluding accessibility of transcription factors and other
regulatory proteins to bind DNA and therefore the ability to
inﬂuence gene expression [3]. Activated transcription factors
(e.g., NF-κB, AP-1, STAT) bind to promoter regions on
genes leading to the recruitment of CREB-binding protein
(CBP)/adenoviralproteinE1A(p300)andothercoactivation
proteinstoformatranscriptionalinitiationcomplex,leading
to histone acetylation and gene transcription [4]. It is widely
recognised that aberrant gene transcription resulting in
either HAT inactivation or HDAC overexpression can lead to
increased tumour cell proliferation (a major mechanisms of
oncoproteins) as well-regulating proinﬂammatory responses
[5]. In humans, a total of 18 HDAC members have been
identiﬁed and characterized to date, falling into four classes:
class I (HDAC1,2,3,8), class II (HDAC4,5,6,7,9,10) and
class III (Sir2-like deacetylase sirtuins1-7), and class IV
(HDAC11) [6, 7]. Both class I and class II are involved
in regulating proinﬂammatory responses as well as cell
proliferation and diﬀerentiation while the functions of class
III HDACs are not fully understood. Class IV HDAC11
has been recently characterized as enzymes modulating the
balance between immunity and tolerance [8].
2. HistoneDeacetylasesand Immunity
The role of HDACs in the epigenetic regulation of innate
and adaptive immunity is of signiﬁcant interest. Under-
standing the level of HDAC expression within the immune
system would assist the development of more targeted2 ISRN Hematology
immunomodulatory therapeuticstrategies.Themultitude of
HDAC isoforms may elicit further control over the complex
immune response dynamics during eﬀector cell functioning.
Themolecularmechanism(s)bywhichHDACsmediatetheir
biological activity are diverse, either by direct inhibition
of gene transcription or indirectly through modulation of
nuclear transcription factors such as NF-κB.
Transcription factors such as NF-κB, GATA-3, T-bet, and
Foxp3 are integral to the development of immunity. For
the NF-κB family proteins, p65 (RELA) and p50 (NFκB1),
interaction with HDAC1 and HDAC2 has wide-ranging
eﬀects on the immune system [9]. While HDAC1 and
HDAC2 have been shown to bind with the NF-κBf a m i l y
corepressor protein p65 and downregulate NF-κB-mediated
gene transcription, in unstimulated cells,this is also achieved
by HDAC1 interactions with another NF-κB corepressor,
p50 [10–12]. Upon activation, this complex is displaced by
phosphorylatedp65andthetranscriptionalcoactivator,CBP,
increasing gene transcription. HDAC enzymes are therefore
critical in the balance of inﬂammatory responses mediated
by IL-6, IL-8, IL-1β, and GM-CSF by regulating the histone
acetylation status of NF-κB and AP-1. Evidence also suggests
that NF-κB activation status is also dependent on HDAC3
in the regulation of target gene promoter hyperacetylation
(e.g., IκB-α,I L - 2 ,I L - 6 )[ 13]. Moreover, maintenance of
NF-κB acetylation occurs following cytosolic IκB-α binding
to HDAC1 and HDAC3, preventing inactivation of NF-κB
transcription [14]. HDAC3-mediated deacetylation of p65
results in shuttling of the NF-κB complex from the nucleus
to the cytoplasm, thus controlling the proinﬂammatory
response [11]. Oxidative stress producing reactive oxygen
species in the context of cigarette smoking, chronic obstruc-
tive pulmonary disease, and air pollutants are all known to
inhibit HDAC activity, thereby enhancing transcription of
proinﬂammatory genes via NF-κB and exacerbating these
activities [15, 16]. Similar HDAC eﬀects have been reported
in animal models of trauma/haemorrhage in the repression
of proinﬂammatory responses [17]. More recently, interest
in the role of environmental exposures during pregnancy on
epigenetic changes in the fetus that either silence or activate
gene expression may provide clues to critical pathways
leading to disease susceptibility and pathogenesis.
HDAC activity also inhibits dendritic cell (DC) function
by repressing the acetylation of histone and nonhistone
proteins such as STAT-3 [18]. This negative regulation of
DC function has important implications in the induction
of eﬀector immunity. The class I HDAC, HDAC1, has been
previously reported to repress TLR-inducible genes as well
as the IL-12p40 promoter although this is not completely
understood since recent studies have shown upregulated
IL-12p40 gene in DCs by HDACs [19], possibly by post-
translational modiﬁcations that enhance transcription factor
recruitment to promoter regions. It was proposed that
certain HDACs could reverse the acetylation of nonhistone
proteins such as transcription factors p53, GATA, SMAD7,
and NF-κB.
Epigenetic mechanisms such as DNA methylation and
histone modiﬁcations have been associated with the tran-
scription and expression of the Foxp3 gene [20]a n dw e r e
involvedinFoxp3+ Tregdiﬀerentiation into IL-17producing
cells. In addition, the ﬁnding that histone H3 and H4
acetylation was associated with a conserved region within
the Foxp3 locus for CD4+CD25+ Treg but not conventional
CD4+CD25− T cells, similar to that for DNA methylation,
suggests an important role for epigenetics in maintain-
ing Foxp3 expression. Dysregulation of this response may
favour enhanced HDAC activity which would destabilize this
process and may lead to exacerbated immunopathologies.
In addition, both Th2 cytokine and GATA-3-driven T-
cell responses as well as Th17 cells are also activated
following redox-induced HDAC inhibition [21–23]. The
Th17 phenotype is partly controlled by TGF-β (via SMAD
signalling) which inhibits both T-bet and GATA-3 and
subsequent Th1/Th2 cytokine production [24, 25]. A new
member of the HDAC family, HDAC11 (class IV), has
recently been implicated as a critical molecular target in
the immune system that directs activation or tolerance
[8]. Experimental evidence demonstrated that HDAC11
represses IL-10 gene expression in human and murine APCs
leading to immune activation of previously tolerant CD4+
T cells [26]. Conversely, APCs lacking in HDAC11 were
shown to upregulate IL-10 gene expression and can tolerize
antigen-speciﬁc T cells. The manipulation of HDAC11 by
speciﬁc HDAC inhibitors represents a novel approach in the
treatment of a variety of immunological conditions as well as
in the immunotherapy of cancer.
HDAC enzymes could also help control Th1 and Th2
diﬀerentiation of naive CD4+ T cells by reversing the
hyperacetylation of histones 3 and 4 at the IFN-γ promoter
[27]. This would be useful since such epigenetic changes are
stably inherited by fully diﬀerentiated eﬀector T cells [22].
It has been reported that HDACs interact with regulators
of MHC class II gene activation (e.g., CIITA) and act as
molecular switches to turn oﬀ this process [28]. The use
of bioinformatics has helped identify conserved noncoding
regions in the IFN-γ gene that are associated with increased
Th1-speciﬁc H4 acetylation as well as locate T-bet binding
due to the presence of cluster regions containing transcrip-
tion factor binding sites for NF-κB, T-bet, GATA-3, and
STAT-4/6. The HDAC-mediated control of IFN-γ Th1 eﬀects
may be required in the control of certain immunological
conditions. GATA-3 helps maintain repression of Th1 eﬀects
by binding to HDAC enzymes which then interacting with
the IFN-γ gene while allowing stable Th2 diﬀerentiation
[29]. The fact that T-bet can bind directly with GATA-3
to inhibit this activity ensures a balance between these Th
lymphocyte functions [30].
3.HistoneDeacetylaseInhibitorsas
Therapeutic Immunomodulators
The clinical use of HDAC inhibitors (HDACi) has been
mainly focused on the treatment of cancer based on the
documented antiproliferative activities involving regulation
of gene expression, cell cycle arrest, apoptosis, and antian-
giogenesis eﬀects [2, 31–33]. Since the expression of HDACs
inﬂuences the development and diﬀerentiation of immune
responses, the identiﬁcation of a variety of molecules ableISRN Hematology 3
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Figure 1: Schematic representation of HDACi immunomodulation. (1) HDACi such as Trichostatin A and SAHA suppress the activity
of class I/II HDAC enzymes (2). This reverses the acetylation status, leading to (hyper)acetylation of both (3) histone and (4) nonhistone
proteins such as nuclear transcription factors. Together, chromatin remodelling and immune gene expression is altered and, in the context
of the immune system, can lead to immunomodulation (5). Among the pleiotropic activities of HDACi, activation of Treg cells limits
the extent of inﬂammatory-mediated tumourigenesis as well as the development of Th17 cells. HDACi also directly inhibit the activity of
Th1 cells mainly by repression of the Th2 regulator, GATA-3. Inhibition of proinﬂammatory APC function is also mediated by HDACi by
modulating NF-κB activation status. These properties of HDACi are also important in the immunosurveillance of cancer by upregulating
speciﬁc markers that enhance tumour antigenicity and targeted immune system-mediated cytotoxicity CD8+ T cells and NK cells.
to inhibit particular HDAC enzymes (HDACi) oﬀers an
exciting and novel approach to the treatment of immune-
mediated diseases (Figure 1). More speciﬁcally, HDACi with
reported eﬀects on autoimmune disease, transplantation,
and infection will be discussed here in after.
HDAC inhibitors (HDACi) are a potential source of
novel immunomodulatory drugs aimed at treating a wide
range of diseases. In particular, the maintenance of an
anergic state is associated with repression of the IL-2 gene
promoterregion[34,35].Thisoccursasaresultofepigenetic
imprinting that can be inherited over multiple cell division
cycles [36]. CD4+ T-cell activation requires antigenic and
costimulatory signals and is dependent on histone acety-
lation chromatin remodelling at the IL-2 promoter [37].
However, anergy results from the lack of costimulation as
well as histone hypoacetylation of both IL-2 and IFN-γ
promoters where HDAC activity is thought to maintain
this anergic phenotype. Inhibition of HDAC activity in
this context restores histone acetylation in conjunction with
reduced Ikaros expression (that interacts with corepressor
complexes) to relieve this anergic state. The potential use
of HDACi in the treatment of immune disorders or as
adjuvants that direct the generation of speciﬁc immune
phenotypes has signiﬁcant implications in the design of
newpharmacologicalsorprophylacticdrugdesign.Increased
understanding of the biological properties of HDACi will
help delineate how these molecular targets can “switch” the
immune system in response to any given challenge.
Using the pan-HDACi, LAQ824, both upregulation and
downregulation of speciﬁc innate immune genes were found
in TLR4 (LPS) activation of APCs such as monocytes and
DCs[38].HDACi-treatedmurineDCscoculturedwithOVA-
stimulated CD4+ T cells selectively inhibited IFN-γ by
Th1 cells but had no eﬀect on Th2 cytokine production.
Similarly, the addition of another HDACi, sodium butyrate,
a short-chain fatty acid, to DC cultures also inhibits CD1
expression (involved in presentation of lipid antigens) but
not CD83, CD86, or MHC molecules at the protein and
mRNAlevelaswellasTh1cytokineresponses[39].Usingthe
well-characterized class I/II HDACi, Trichostatin A (TSA),
CD4+ T-cell proliferation was inhibited with a concomi-
tant increase in caspase-independent apoptosis in primary
murine T cells [40]. The biological activity TSA was also
demonstrated by suppression of IL-2 gene expression and
NF-κB protein levels. A similar inhibitory eﬀect on human
T cells was observed following HDACi treatment associated
with inhibition of IL-2 secretion by activated T cells, reduced
CD154 (CD40L), CD25 but not CD69 expression, as well as
a reduction in c-myc expression [41]. These immunomod-
ulatory activities of HDACi suggest an important role as
novel therapeutic agents in the amelioration of immune and
inﬂammatory-mediated conditions.
Diﬀerentiation and function of DCs were impaired
following treatment with the HDACi, valproic acid (VPA),
and MS-275 [42]. This was based on the downregulation
of the costimulatory markers CD1a, CD80, CD83, and the
CD54 adhesion marker even in the presence of the TLR3
ligand, poly (I-C) known to induce the expression of these
markers under normal conditions. The eﬀects of VPA and
M S - 2 7 5o na l t e r e dD Cf u n c t i o nw e r ed e m o n s t r a t e dw i t h
impaired stimulatory capacity of allogeneic lymphocytes.
These HDACi eﬀects were mediated through altered NF-κB4 ISRN Hematology
and interferon regulatory factor (IRF) signalling. Using an
alternative HDACi, the fungal metabolite apicidin, Th1 po-
larization of murine bone marrow-derived DCs stimulated
with LPS was suppressed [43]. Apicidin attenuated the secre-
tion of IL-12 and proinﬂammatory cytokines such as IL-6
and TNF-α as well as IFN-γ by T cells that was dependent on
NF-κB inhibition in these cells. A protective eﬀect has also
been established for TSA by blocking PBMC proliferation
and abrogating IFN-γ production by Th1 cells leading to
apoptosis [44]. This provides a mechanism by which HDACi
may be exploited for immunotherapeutic use.
The ability of HDACi to modulate the regulatory im-
mune response has been successful. Treatment of mice with
T S Aa u g m e n t sn a t u r a lF o x p 3 +T r e gc e l l sa sw e l la sT r e gg e n e
expression and suppressive function [45]. TSA treatment of
theseTregcellsalsoincreasedmRNAlevelsofFoxp3,CTLA4,
GITR, and IL-10 that are important in this response. The
TSA activity was associated with acetylation of Foxp3 itself
as well as histones contained within Tregs further evidence
thatnonhistoneproteinsaretargetsforHAT/HDACenzymes
[46]. Moreover, the suppressive Treg function was HDAC9
dependent, providing novel insights into the role of HDAC9
in Foxp3-mediated transcriptional repression [47] and the
potential targeting of this interaction in the manipulation of
immunological responses. Other studies have also demon-
strated the capacity of TSA to induce the diﬀerentiation of
Treg cells from naive T cells via the epigenetic enhancement
of Foxp3 expression [48]. The regulatory activity of histone
deacetylase inhibitors such as TSA and SAHA was also
shown to signiﬁcantly inhibit the secretion of Th1 and
Th17 cytokines (IL-12 and IL-23, resp.) as well as the
selective inhibition of Th1-attracting chemokines (CXCL9,
10, 11) by DCs in an LPS/IFN-γ inﬂammatory model
[49]. Indeed, inﬂammation-induced tumour development
as observed in experimental colitis disease models can be
abrogated by HDACi through modulation of regulatory
immune responses [50]. Since Th17 cells in particular have
important roles in the defence against bacterial infections
as well as in the protection from autoimmune diseases,
these eﬀects of HDACi provide further justiﬁcation for the
furtherinvestigationoftheseagentsinthecontrolofimmune
responses.
4.HistoneDeacetylaseInhibitors
andTransplantation
The role of HDACi in promoting allograft survival and
transplanttoleranceisdependentoncriticalimmuneeﬀector
functions. Trichostatin A has been reported to enhance
allografttoleranceinsynergywithlow-doserapamycintreat-
ment that was dependent on the development of intragraft
Foxp3+ Treg cells [51]. In mouse models of cardiac and islet
transplantation, increased survival times past 100 days were
observed following HDACi treatment with maintenance of
tissue and cellular integrity after transplantation [52]. TSA
also enhances the production of Foxp3+ Treg with suppres-
sive function [53] associated with increased histone H3 and
Foxp3 acetylation in vivo [54]. In a model of experimental
graft-versus-host disease (GVHD) using murine allogeneic
bone marrow transplantation (BMT), pretreatment of bone
marrow-derived DCs with SAHA (a derivative of TSA) up-
regulated expression of the DC-suppressor, indoleamine 2,3-
dioxygenase (IDO) leading to reduced GVHD [55]. This
eﬀect for SAHA was associated with reduced DC-stimulated
expression of CD40 and CD80 in vitro as well as reduced
TLR-mediated proinﬂammatory cytokine secretion. Fur-
thermore, Tregs isolated from HDAC6-deﬁcient mice had
increased FoxP3 and IL-10 mRNA expression compared to
wild-type mice, and these Tregs exhibited increased suppres-
sive activity suggesting an important role for this enzyme
[56]. Indeed, pharmacological inhibition of HDAC6 using
the isoform-speciﬁc inhibitors, tubacin, and tubastatin A
produced similar results and induced long-term cardiac
allograft survival in mice. Similarly, the eﬀect of HDACi such
as SAHA was also found to increase Treg suppressive activity
that was found to correlate with CTLA-4 levels rather than
FoxP3 [57]. Evidence for the role of HDAC11 in transplant
survival has only recently emerged, with inhibition of this
enzyme using short hairpin RNA interference (RNAi) reduc-
ing HDAC11 mRNA and protein levels in liver tissue with a
concomitantincreaseinIL-10followinglivertransplantation
in rats [58]. These changes were associated with increased
survival rates after 1 week, and the eﬀects on IL-10 were
thought to be safer than conventional immunosuppressant
therapy. Modulation of HDAC11 expression was detected in
liver Kupﬀer cells (macrophages) after transplantation [59],
providing a mechanism for tolerance induction. Therefore,
HDACi with immunological activities represent promising
alternatives or adjuncts to current treatment modalities, and
clinical trials involving the use of HDACi will be important.
5.HistoneDeacetylaseInhibitors
and Infection
The eﬀectiveness of HDACi for the treatment of infections
has been mostly studied in the context of HIV. Treatment
of HIV by Highly Active Antiretroviral Therapy (HAART)
does not completely eradicate latently infected cells that
are a source for viral reactivation and increased viral load
[60]. Several in vitro studies have reported the ability of
HDACi to induce viral replication under latency conditions
suggesting that combination therapy consisting of HAART
and HDACi may augment this response [61–63]. Using the
HDACi, valproic acid (VPA), or SAHA in combination with
an NF-κB inducer, prostratin, a higher reactivation of HIV-
1 production was observed in latently infected U1 and J-
Lat cell lines as well as in CD8+-depleted PBMCs from
HIV-1-infected patients receiving HAART where viral load
could not be detected compared to either HDACi alone [60,
62]. The ability of VPA to increase and prolong prostratin-
induced NF-κB DNA binding was postulated as being part
of the regulatory NF-κB pathway modulated by histone
and/or nonhistone changes [64]. Indeed, VPA reversed the
repressive activity of the nuc-1 nucleosome [65]( w h i c h
is immediately downstream of the HIV-1 transcription
promoter) and induced the acetylation of histone H4. Fur-
thermore, HDAC3-speciﬁc inhibition by VPA was necessary
to activate latent HIV in Jurkat cells in vitro, although thisISRN Hematology 5
eﬀect was only moderate [66] .T r e a t m e n tw i t hS A H Ai n
an LPS mouse model of septic shock improved survival
rates associated with increased liver anti-inﬂammatory IL-
10 levels while decreasing proinﬂammatory IL-6 and MAP
kinase production [67]. The biological activities of HDACi
in the context of malaria and fungal diseases have also been
examined with limited success [68].
In contrast, HDACi treatment has also been shown
to impair host defense against bacterial infections. Recent
studies have shown that HDAC inhibition by TSA, SAHA,
and VPA can impair innate immune responses to TLR
agonists by reducing the expression of genes associated
with microbial sensing (C-type lectins, adhesion molecules,
and others) as well as a range of cytokine and chemokine
genes [69], thereby increasing susceptibility to infection.
Interestingly, while VPA increased mortality from lethal C.
albicans or K. pneumonia infection in mice, it increased
survival in mouse models of toxic shock. Reduced killing
of E. coli and S. aureus was also observed following in vitro
treatment of murine macrophages with TSA and VPA, with
impaired phagocytosis and reactive oxygen and nitrogen
species generation [70]. Together, these data reveal the
complex nature of HDACi eﬀects and highlight the need for
more studies in this context.
6.HistoneDeacetylaseInhibitors
andImmune-MediatedDisease
Emerging data on the experimental properties of HDACi
have centred on immune-mediated diseases such as immun-
odeﬁciency conditions and autoimmunity. Many immun-
odeﬁciency conditions develop early in life and persist for
many years into adulthood, often with limited treatments.
New therapies that improve clinical outcomes will therefore
be of signiﬁcant advantage. The HDACi VPA was shown to
signiﬁcantly reduce lymphoproliferation in a murine model
of autoimmune lymphoproliferative syndrome (ALPS) [71].
This is a condition characterized by lymphadenopathy,
splenomegaly, hypergammaglobulinemia, elevated IL-10,
and accumulation of double-negative T cells [72–74] asso-
ciated with mutations in the Fas gene that is critical for
lymphocyte homeostasis and peripheral immune tolerance
[75].VPAandanotherHDACi,depsipeptide,inducedPBMC
apoptosis in healthy individuals and ALPS patients in vitro,
although depsipeptide was associated with reduced bone
marrow cellularity [71]. In addition, VPA induced histone
acetylation in splenocytes that persisted in the absence of
serum VPA. Similar results have also been reported for TSA
[76].Itis believed thatthe clinicalactivityofHDACi in ALPS
patients may be more eﬀective due to a lack of a functional
extrinsic apoptosis pathway.
The role of HDACi in the treatment of multiple scle-
rosis (MS) was identiﬁed by early studies indicating that
neuronal traits may be modulated by histone acetylation
of neuronal genes [77]. The speciﬁc repressor protein,
repressor element 1 silencing transcription factor (REST), is
important since dysregulated REST contributes to neuronal
loss [78]. Corepressor complexes of REST and HDACs have
been isolated and recruitment of HDACs represses gene
expression, with class I and II HDACs being critical for
neuron survival and diﬀerentiation [79, 80]. In MS, HDACi
have been shown to upregulate MHC class II genes since
HDAC1and2repressthisgeneexpression[81,82].However,
HDACi have been shown to ameliorate MS pathogenesis by
preventing IFN-γ-induced B7.1 upregulation and enhancing
B7.2 expression on T cells leading to a Th2 phenotype
shift [83]. Furthermore, the therapeutic eﬀects of HDACi
may be associated with matrix metalloproteinase (MMP)
expression since this is important in the inﬂammatory cell
inﬁltration observed in MS. While the HDACi, sodium
butyrate, increased MMP-9, another HDACi, apicidin, had
no such eﬀect while also inhibiting MMP-2 activity in vitro
[84, 85]. Using the murine model of MS, experimental
autoimmune encephalomyelitis (EAE), the HDACi TSA
reversed the myelin-oligodendrocyte-glycoprotein- (MOG-)
induced EAE via proinﬂammatory cytokine repression as
well as histone hyperacetylation and inhibition of axonal
apoptosis by caspase-dependent mechanisms [86].
In another model of autoimmune disease, HDAC inhi-
bition using TSA and SAHA reduced the IFN-γ and IL-1β-
mediated beta-cell destruction and reduced insulin secretion
characteristic of type 1 diabetes mellitus in vitro [87]. In
this example, inhibition of NO and beta cell apoptosis
was revealed and was NF-κB dependent, further indicat-
ing the clinical utility of HDACi in the protection from
inﬂammatory-mediateddiseases.TheutilityofHDACiinthe
treatmentofinﬂammatoryconditionsalsoextendstoasthma
and other allergic diseases. In one study, TSA was shown to
reverse airway hyperresponsiveness (AHR) in an Aspergillus
fumigatus mouse model of asthma [88]. Similar results were
also reported for TSA in an OVA mouse model of asthma,
with reduced AHR, lower lymphocytic and eosinpohilic
inﬁltrate in the BALF, as well as reduced IL-4, IL-5, and IgE
levels in the BALF [89].
7.HistoneDeacetylaseInhibitors
and Cancer Immunotherapy
Altered HDAC function and recruitment could result in
enhanced hypoacetylation and repression of genes required
for normal growth and development and disruption of
the HDAC/HAT balance favouring abnormal acetylation
and inappropriate protein expression could provide the
molecular trigger that directs pathological outcomes [5, 90,
91]. The discovery that HDAC function is dysregulated in
cancer and has a pivotal role in tumourigenesis justiﬁes the
use of HDAC inhibitors as an eﬀective approach to restore
this balance [92].
An exciting area of cancer research has focused on the
therapeutic eﬃcacy of HDACi in modulating antitumour
immunity. Of the many diverse biological HDACi activities,
recent evidence suggests that tumour immunosurveillance
may be enhanced by direct manipulation of tumour cells
or indirectly via changes in the immune microenvironment
[1]. Such immunological niches could provide enhanced
regulation of tumour growth and development. Several
studies have shown that tumour antigenicity is enhanced
following HDACi treatment, thereby preventing tumour6 ISRN Hematology
escape. HDACi such as sodium butyrate, TSA, and trapoxin
AamongothersupregulateMHCclassIandclassIIproteins,
CD40, CD80, and CD86 antigens necessary for costimu-
lation, as well as adhesion molecules such as intercellular
adhesion molecule-1 (ICAM-1) on acute myeloid leukemic
(AML)cells,humanneuroblastomatumourcells,andmouse
plasmacytoma cells in vitro [93, 94]. These results suggest
an important function of HDACi in tumour eradication.
Moreover, TSA, SAHA, VPA, and sodium butyrate were
also found to increase the expression of the MHC class I-
related chain A (MICA) and chain B (MICB) on tumour
cells [95, 96]. The MICA and MICB proteins are ligands
for Natural Killer (NK) group 2, member D (NKG2D)
activating receptors on NK cells, CD8+ T cells, and γδ
T cells important for the immune-targeted destruction of
tumour cells. In the case for TSA, the mechanisms for
this tumour cytotoxicity were associated with increased
histoneH3acetylationandreducedHDAC1expressionatthe
MICA and MICB promoters regions [97]. Furthermore, the
immunogenicity of epithelial tumour cells was increased by
TSA via upregulating UL16-binding protein (ULBP) expres-
sion (an NKG2D ligand) and enhancing NK cell-mediated
tumour cytotoxicity related to the release of HDAC3 from
the ULPB promoter [98]. Enhanced tumour cell cytotoxicity
also occurs following RNAi-mediated HDAC11 inhibition,
increasing OX40L expression in Hodgkin lymphoma cell
lines associated with elevated TNF-α and IL-17 levels in the
supernatant [99]. In contrast with other HDACi, inhibition
of HDAC11 in this study lowered IL-10-producing Treg
numbers which favoured the elimination of these tumour
cells. Taken together, this suggests that HDACi exhibit a
variety of eﬀects based on the disease context and their tissue
and cellular speciﬁcity.
HDACi have also been successful in the prevention and
treatment of cancer through therapeutic vaccination. Treat-
ment with TSA or depsipeptide augmented the expression
of the cancer vaccine target, Cancer/Germ-line family of
antigens (CG antigens), as well as MHC and costimulatory
molecules on tumours, facilitating immune system targeting
[100]. In addition, TSA also enhanced the expression of
MHC class II, CD40, and B7-1/2 antigens on B16 melanoma
cells that resulted in the induction of IFN-γ-secreting CD8+
T cells and NK cells [101]. However, the mechanism(s)
by which HDACi augment tumour clearance is not fully
understood. Contrasting these HDACi functions, HDACi
such as TSA were implicated in assisting tumour escape
from the immune system by decreasing the presentation and
killing of tumour cells by CD8+ T cells [102].
Given the immunomodulatory properties of HDACi
described previously, enhanced antitumour immunity could
also result from altered cytokine proﬁles. Suppression of
the proinﬂammatory cytokines, IL-1, TNF-α,a n dI F N - γ
h a sb e e nr e p o r t e di ns t u d i e so fa l l o g e n e i cb o n em a r r o w
transplantation [55] possibly via epigenetic changes at the
promoter/enhancer regions of cytokine genes as well as
regulatory transcription factors (e.g., STAT1, 3) [1]. An
example of this was observed for the HDACi, SAHA, by
altering the Th1/Th2 cytokine balance favouring Th1 by
inhibiting STAT6-mediated IL-5 production and secretion
of Thymus and Activation-Regulated Chemokine (TARC or
CCL17) as well as increasing the levels of IL-10 and IL-13 in
Hodgkin lymphoma cell lines in vitro [103].
8. New Generation Histone
DeacetylaseInhibitors
The mechanism by which HDAC inhibitors mediate the
diverse antitumour activities is not fully understood. While
the pan-HDACi, SAHA and panobinostat (LBH-589), are
eﬀective against many diﬀerent tumours and are generally
well-tolerated, recent evidence suggests that more tumour-
speciﬁc reagents are required [104–107]. The accumulating
data on HDAC expression in tumours will allow researchers
to develop particular isoform-speciﬁc candidates with
increased eﬃcacy. For instance, in haematological cancers,
HDAC1, 2, and 6 predominate while for solid tumours,
HDACexpressionisvariablewithHDAC1-3(gastricandcol-
orectal cancer), HDAC1, 4–7, 10 (liver cancer) and HDAC1,
3, 6 (breast cancer) described [108]. More speciﬁc com-
pounds may modulate a smaller number of genes speciﬁc
for a particular disease as well as exhibiting a lower toxicity
proﬁle compared to the reported 22% of genes said to be
regulated by pan-HDACi [32, 109]. The level of HDAC
expression can also be thought of as a biomarker for certain
responsive tumour types in addition to the acetylation status
of histone proteins during clinical trials of HDACi. However,
the identiﬁcation of novel biomarkers that can predict the
response to treatment may be more beneﬁcial in targeting
particular HDACi in speciﬁc cases [110].
T h er e q u i r e m e n tf o rm o r es p e c i ﬁ ca n de ﬃcacious anti-
cancer treatments has led to implementation of natural
product screening programs to identify novel compounds
thatexhibitsuchproperties.Naturallyoccurringcompounds
are a rich resource for potential new drug candidates [111].
Similar to the National Cancer Institute’s extensive natural
product screening programs last century that provided
the medical community with the now commonly used
anticancer drugs paclitaxel, vincristine, and vinblastine, new
generation HDACi have also been identiﬁed from nature.
In particular, compounds derived from the rhizomes of
Zingiber zerumbet, a south-east Asian ginger, and the roots
ofPleuropterusciliinervisexhibitedHDAC-associatedgrowth
inhibitory activity on several human tumour cell lines [112,
113]. Pomiferin isolated from the fruits of Maclura pomifera
could also inhibit growth of human tumour cells but was
lower than that for SAHA [114]. While structural similarities
of these novel compounds to classical HDACi such as SAHA
were apparent, this may not necessarily be suﬃcient to
predict HDACi activity, as one such compound was found
to possess no such inhibitory activity towards ARP-1 human
myeloma cells in vitro [115].
9. Conclusions andFutureDirections
The therapeutic potential of HDACi oﬀers an alternative
approach to the treatment of a wide variety of conditions
such as cancer and immune-mediated diseases. The pleio-
tropic eﬀects of HDACi include inhibition of cancer cellISRN Hematology 7
proliferationanddiﬀerentiationaswellasinducingproapop-
totic and antiangiogenesis events. In relation to the immun-
omodulatory properties of HDACi described in this paper,
epigenetic regulation of histone and nonhistone transcrip-
tion factors inﬂuence important pathways for the generation
of eﬀective immune responses. Moreover, HDACi prevent
the ability of tumours to evade the immune system by en-
hancing host immunosurveillance and inducing appropriate
localimmuneeﬀectorfunctions.Thesearchformorespeciﬁc
compounds from sources such as plants may unearth highly
eﬃcacious next-generation HDACi of clinical importance.
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